HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.

Abstract
The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo. Participants were community dwelling adults aged 70 years and older in Australia, 65 years and older in the United States, all free of a history of dementia or cardiovascular disease and of any disease expected to lead to death within five years. CKD was defined as present at baseline if either eGFR under 60mL/min/1.73m2 or urine albumin to creatinine ratio 3 mg/mmol or more. In 4758 participants with and 13004 without CKD, the rates of a composite endpoint (dementia, persistent physical disability or death), major adverse cardiovascular events and clinically significant bleeding in the CKD participants were almost double those without CKD. Aspirin's effects as estimated by hazard ratios were generally similar between CKD and non-CKD groups for dementia, persistent physical disability or death, major adverse cardiovascular events and clinically significant bleeding. Thus, in our analysis aspirin did not improve outcomes in older people while increasing the risk of bleeding, with mostly consistent effects in participants with and without CKD.
AuthorsRory Wolfe, James B Wetmore, Robyn L Woods, John J McNeil, Hugh Gallagher, Paul Roderick, Rowan Walker, Mark R Nelson, Christopher M Reid, Raj C Shah, Michael E Ernst, Jessica E Lockery, Andrew M Tonkin, Walter P Abhayaratna, Peter Gibbs, Erica M Wood, Suzanne E Mahady, Jeff D Williamson, Geoffrey A Donnan, Geoffrey C Cloud, Anne M Murray, Kevan R Polkinghorne
JournalKidney international (Kidney Int) Vol. 99 Issue 2 Pg. 466-474 (02 2021) ISSN: 1523-1755 [Electronic] United States
PMID32920022 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Aspirin
Topics
  • Aged
  • Aged, 80 and over
  • Aspirin (adverse effects)
  • Australia
  • Cardiovascular Diseases (epidemiology, prevention & control)
  • Hemorrhage (chemically induced)
  • Humans
  • Renal Insufficiency, Chronic (complications, diagnosis, drug therapy)
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: